ENDRA Life Sciences Inc. filed its 10-K on Mar 16, 2023 for the period ending Dec 31, 2022. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.291 USD | -2.68% | -10.04% | -86.31% |
May. 10 | ENDRA Life Sciences Inc. Provides Earnings Guidance for the Quarter Ended March 31, 2024 | CI |
Mar. 28 | Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.31% | 3.3M | |
+25.78% | 44.96B | |
-0.76% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.46% | 26.08B | |
-21.14% | 19.03B | |
+5.97% | 12.75B | |
+28.26% | 12.06B | |
-3.20% | 11.75B |
- Stock Market
- Equities
- NDRA Stock
- News ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. Auditor Raises 'Going Concern' Doubt